Trials / Completed
CompletedNCT01158157
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Emergent BioSolutions · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACAM2000 | Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle. |
Timeline
- Start date
- 2010-09-13
- Primary completion
- 2012-02-14
- Completion
- 2012-02-14
- First posted
- 2010-07-08
- Last updated
- 2024-03-18
- Results posted
- 2019-03-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01158157. Inclusion in this directory is not an endorsement.